source
- BioNTech stops Phase 2 colorectal cancer mRNA vaccine trial after futility findingsBioNTech announced that it is ending its Phase 2 study of a personalized mRNA vaccine for resected colorectal cancer after the trial failed to show the needed benefit. The news sent the company’s s…
- BioXcel files for Chapter 11 bankruptcy, selling assets to Teva for up to $125 MBioXcel Therapeutics announced it has filed for Chapter 11 bankruptcy and plans to sell all of its assets. Teva Pharmaceuticals will serve as the stalking horse bidder, proposing an upfront paymen…